Document is current
Any future updates will be listed below
-
Authors
Medland, Sarah M. https://orcid.org/0009-0000-1312-8458
Bainbridge, Jamie https://orcid.org/0009-0005-0903-3604
Cawson, Matthew https://orcid.org/0000-0001-7175-0720
Mealing, Stuart J. https://orcid.org/0000-0002-2564-1440
Yudina, Anna
Eastwood, Isabel https://orcid.org/0009-0007-3959-9101
de Kreuk, Arne https://orcid.org/0000-0002-9715-9063
Besser, Martin https://orcid.org/0000-0003-1004-6232
Tsouana, Eva
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 8 September 2025
First Online: 8 October 2025
Declarations
:
: AY and MC are employees of Terumo BCT Europe. AdK reports speaker fees and honoraria for Pfizer. MB reports advisory boards for Agios, Forma, Octapharma, and GBT Novartis; honoraria for lecturing for Terumo, Sanofi, and Pfizer; support to attend meetings for Novartis, Pfizer, and GBT; and support for patient activities for Agios, Terumo, and Novartis. SMM, JB, SJM, IE, and ET declare no competing interests.
: Not applicable.
: Not applicable.
: Not applicable.
: The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
: The model developed for this research is not publicly available.
: MC and AY conceptualised the research problem. SMM, JB, and SJM conceptualised the model and design. All authors contributed to and approved the final model design. SMM and JB collected data, built the model, and ran and interpreted the cost-effectiveness analysis with assistance from SJM and IE. SMM and JB wrote the manuscript. All authors contributed to the manuscript content and review.
